Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • US FDA warns Abbott...

    US FDA warns Abbott Labs over heart device problems

    Written by supriya kashyap kashyap Published On 2017-04-14T13:08:03+05:30  |  Updated On 14 April 2017 1:08 PM IST
    US FDA warns Abbott Labs over heart device problems

    The U.S. Food and Drug Administration issued a warning letter to Abbott Laboratories, citing manufacturing flaws with a range of cardiovascular devices acquired with its purchase of St. Jude Medical in January for $25 billion.


    The letter, dated April 12 and made public, sent Abbott's shares down 2 percent to $42.61.


    The FDA, which said the company failed to disclose at least one death associated with one of the devices, said an inspection of the company's facility in Sylmar, California, raised questions about the safety of several implantable defibrillators and its Merlin@home monitor, which allows doctors to care remotely for patients with cardiac devices.


    The FDA investigation showed that lithium batteries in the devices were draining prematurely and that the company had "underestimated the occurrence of the hazardous situation."


    Abbott said in a statement it has a "strong history and commitment to product safety and quality." It said the FDA's inspection took place in February and that Abbott responded on March 13 describing corrective actions it was taking.


    "We take these matters seriously, continue to make progress on our corrective actions, will closely review FDA's warning letter, and are committed to fully addressing FDA's concerns," the company said.


    The FDA said Abbott had provided implementation dates for several corrective actions but failed to provide evidence that the actions had actually been implemented.


    Analysts said the FDA may now delay approval of new devices that can be used inside an MRI machine that the company had expected to see approved by the end of the year.


    That could help rivals Medtronic Plc, which has such devices on the market and Boston Scientific Corp which expects to launch similar devices in the fourth quarter.


    "These two companies stand to benefit in the event Abbott's approvals are delayed," Glenn Novarro, an analyst at RBC Capital Markets, said in a research note.


    The affected devices, known as implantable cardioverter defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) help pace slow heart rhythms and slow dangerously fast rhythms.


    In October St. Jude said it would recall certain models due to reports of battery failure caused by deposits of lithium forming within the battery and causing a short circuit.


    In its letter, the FDA said the company repeatedly concluded that the cause of premature depletion "could not be determined" even though the company's supplier had provided evidence that it was due to lithium deposits, known as lithium cluster bridging.

    AbbottBostonCardiac Resynchronization Therapy DefibrillatorFDA warningFDA Warning LetterGlenn Novarroheart deviceimplantable cardioverter defibrillatorMedtronicSt Jude Medical IncUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok